Tumor necrosis factor receptor 1–Tumor necrosis factor alpha protein-protein interface (TNF-R1–TNFα PPI)

The Tumor necrosis factor receptor 1–Tumor necrosis factor alpha (TNF-R1–TNFα) protein-protein interface is a pivotal structural site that mediates the biological activity of one of the most potent pro-inflammatory cytokines in the human body. TNFα, primarily produced by activated macrophages, functions as a homotrimer that binds to the extracellular domain of TNF-R1, leading to receptor trimerization and the initiation of intracellular signaling pathways such as NF-κB and MAPK, as well as programmed cell death (Source: UniProt P19438, P01375). This specific interface is a major driver of systemic inflammation and is implicated in the pathogenesis of various autoimmune diseases, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease (Source: PubMed PMC4159116). Historically, this target has been successfully addressed using biologics like monoclonal antibodies and decoy receptors that prevent the cytokine from interacting with its receptor (Source: FDA Label Humira). More recently, drug discovery has shifted toward identifying small-molecule inhibitors that can directly disrupt the PPI or stabilize an inactive conformation of the TNFα trimer, offering potential oral alternatives to injectable biologics (Source: Nature Communications 10, 5795). Modulating this interface is highly effective for treating chronic inflammation but requires careful monitoring due to the risk of serious infections and potential malignancy associated with prolonged TNF suppression (Source: StatPearls, TNF Inhibitors).

Other names

TNF-R1/TNFα complexTNFRSF1A-TNF interfaceCD120a-TNF interfaceTumor necrosis factor receptor superfamily member 1A–Tumor necrosis factor interface

Competitive or allosteric inhibition of the binding between trimeric TNFα and the extracellular domain of TNF-R1, preventing receptor trimerization and downstream pro-inflammatory or pro-apoptotic signaling.